Синдром Когана – новая нозология в современной классификации системных васкулитов. Клиническое наблюдение и обзор литературы
Аннотация
Представлено клиническое наблюдение типичного варианта синдрома Когана (СК) – новой нозологической формы современной классификации системных васкулитов (СВ), принадлежащей к группе вариабельных васкулитов. В обзоре литературы подробно освещены проблемы диагностики и лечения этого редкого заболевания.
СК характеризуется воспалительным поражением глаз (интерстициальный кератит, увеит, эписклерит) и патологией органа слуха (нейросенсорная тугоухость, вестибулярные нарушения) с возможным развитием васкулита другой локализации, аортита, поражения аортального и митрального клапанов. Системное поражение с вовлечением ЛОР-органов и глаз требует исключения гранулематоза с полиангиитом (Вегенера) и дифференциальной диагностики с широким спектром заболеваний. Представленные данные подчеркивают необходимость междисциплинарного сотрудничества ревматологов, оториноларингологов, аудиологов, офтальмологов, кардиологов для совершенствования диагностики и лечения этой формы СВ.
Об авторе
Т. В. Бекетова
ФГБНУ Научно- исследовательский институт ревматологии им. В.А. Насоновой, Москва
Россия
Россия
115522 Москва, Каширское шоссе, 34А
Список литературы
1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi: 10.1002/art.37715
2. Бекетова ТВ, Насонов ЕЛ. Современная классификация системных васкулитов. Терапевтический архив. 2014;(5):94-8 [Beketova TV, Nasonov EL. Modern classification of systemic vasculitis. Terapevticheskii arkhiv. 2014;(5):94-8 (In Russ.)].
3. Cogan DG. Syndrome of nonsyphilitic intersticial keratitis and vestibuloauditory symptoms. Arch Oftalmol. 1945;33:144-9. doi: 10.1001/archopht.1945.00890140064007
4. Cody DT, Williams HL. Cogan's syndrome. Laryngoscope. 1960;70:447-78. doi: 10.1288/00005537-196004000-00010
5. Lunardi C, Bason C, Leandri M, et al. Autoantibodies to the inner ear and endothelial antigens in Cogan's syndrome. Lancet. 2002;360:915-21. doi: 10.1016/S0140-6736(02)11028-2
6. Lobo DR, Garcia-Berrocal JR, Ramirez-Camacho R. New prospects in the diagnosis and treatment of immune-mediated inner ear disease. World J Methodol. 2014;4:91-8. doi: 10.5662/wjm.v4.i2.91
7. Matsuoka AJ, Harris JP. Autoimmune inner ear disease: a retrospective review of forty-seven patients. Audiol Neurotol. 2013;18:228-39. doi: 10.1159/000351289
8. Bonaguri C, Orsoni JG, Zavota L, et al. Anti-68 kDA antibodies in autoimmune sensorineural hearing loss. Are theses autoantibodies really a diagnostic tool? Autoimmunity. 2007;40:73-8. doi: 10.1080/08916930601119377
9. Bonaguri C, Orsoni JG, Russo A, et al. Cogan's syndrome: antiHsp70 antibodies are a serological marker in the typical form. Israel Med Assoc J. 2014;16:285-8.
10. Vinceneux P Cogan's syndrome. Orphanet Encyclopedia. 2005;(2):1-7. Available from: https://www.orpha.net/data/patho/GB/uk-cogan.pdf
11. Gluth MB, Baratz KH, Matteson EL, Driscoll CL. Cogan syndrome: a retrospective review of 60 patients throughout a half century. Mayo Clin Proc. 2006;81:483-8. doi: 10.4065/81.4.483
12. McDonald TJ, Vollertsen RS, Younge BR. Cogan's syndrome: audiovestibular involvement and prognosis in 18 patients. Laryngoscope. 1985;95:650-4.
13. Murphy G, Sullivan MO, Shanahan F, et al. Cogan's syndrome: present and future directions. Rheumatol Int. 2009;29:1117-21. doi: 10.1007/s00296-009-0945-0
14. Haynes BF, Kaiser-Kupfer MI, Mason P, Fauci AS. Cogan syndrome: studies in thirteen, long-term follow-up and a review of literature. Medicine. 1980;59:426-41. doi: 10.1097/00005792- 198011000-00003
15. Baumann A, Helbling A, Oertle S, et al. Cogan's syndrome: clinical evolution of deafness and vertigo in three patients. Eur Arch Otorhinolaryngol. 2005;262:45-9. doi: 10.1007/s00405-004-0738-8
16. Greco A, Gallo A, Fusconi M, et al. Cogan's syndrome: An autoimmune inner ear disease. Autoimmun Rev. 2013;12:396-400. doi: 10.1016/j.autrev.2012.07.012
17. Grasland A, Pouchot J, Hachulla E, et al. Typical and atypical Cogan's syndrome: 32 cases and review of literature. Rheumatology. 2004;43:1007-15. doi: 10.1093/rheumatology/keh228
18. Agostinho S, Marques MC, Simao MA, Dias O. Cogan's syndrome: a retrospective study of 22 years. J Otol Rhinol. 2015;4:4. doi: 10.4172/2324-8785.1000233
19. Lepur D, Vranjican Z, Himbele J, et al. Chlamydia pneumoniae infection as a trigger for a Cogan's syndrome. J Infect. 2006;52(3):223-6. doi: 10.1016/j.jinf.2005.04.008
20. Azami A, Maleki N, Hormozi MK, Tavosi Z. Interstitial keratitis, vertigo, and vasculitis: typical Cogan's syndrome. Case Rep Med. 2014;2014:Article ID 830831, 4 p. doi: 10.1155/2014/830831
21. Gauthier AS, Delbosc B. Focus on interstitial keratitis. J Fr Ophtalmol. 2012;35:726-34. doi: 10.1016/j.jfo.2012.03.003
22. Knox CM, Holsclaw DS. Interstitial keratitis. Int Ophthalmol Clin. 1998;38(4):183-95. doi: 10.1097/00004397-199803840-00017
23. Son HJ, Ulualp SO. Course of auditory impairment in Cogan's syndrome. Am J Otolaryngol. 2009;30:65-8. doi: 10.1016/j.amjoto.2008.02.003
24. Kondo Y, Ito S, Ohi Y, et al. Atypical Cogan's syndrome with aortitis. Intern Med. 2009;48(12):1093-7. doi: 10.2169/internalmedicine.48.1917
25. Udayaraj UP, Hand MF, Shilliday IR, Smith WG. Renal involvement in Cogan's syndrome. Nephrol Dial Transplant. 2004;19(9):2420-1. doi: 10.1093/ndt/gfh380
26. Brogan K, Eleftheriou D, Rajput K, et al. Tubulointestitial nephritis, uveitis, hearing loss and vestibular failure: TINU-atypical Cogan's overlap syndrome. Rheumatology (Oxford). 2012;51(5):950-2. doi: 10.1093/rheumatology/ker443
27. Vollertsen RS, McDonald TJ, Younge BR, et al. Cogan's syndrome: 18 cases and a review of the literature. Mayo Clin Proc. 1986;61:344-61. doi: 10.1016/S0025-6196(12)61951-X
28. Pagnini I, Zannin ME, Vittadello F, et al. Clinical features and outcome of Cogan syndrome. J Pediatr. 2012;160:303-7. doi: 10.1016/j.jpeds.2011.07.051
29. Mazlumzadeh M, Matteson EL. Cogan's syndrome: an audiovestibular, ocular, and systemic autoimmune disease. Rheum Dis Clin North Am. 2007;33(4):855-74. doi: 10.1016/j.rdc.2007.07.015
30. Lefebvre PP, van de Water TR. Connexins, hearing and deafness: clinical aspects of mutations in the connexin 26 gene. Brain Res Rev. 2000;32(1):159-162. doi: 10.1016/S0165-0173(99)00075-2
31. Dong Y, Roos M, Gruijters T, et al. Differential expression of two gap junction proteins in corneal epithelium. Eur J Cell Biol. 1994;64(1):95-100.
32. Montes S, Rodriguez-Muguruza S, Soria V, Olive A. Atypical Cogan' syndrome associated with sudden deafness and glucocorticoid response. Reumatol Clin. 2014;10(4):267-8. doi: 10.1016/j.reuma.2013.11.005
33. Helmchen C, Arbusow V, Jä ger L, et al. Cogan's syndrome: clinical significance of antibodies against the inner ear and Cornea. Acta Otolaryngol. 1999;119:528-37. doi: 10.1080/00016489950180748
34. Еrsal E, Ugur M, Seven B, et al. The importance of FDGPET/CT in Cogan's syndrome. Mol Imag Radionucl Ther. 2014;23(2):74-5. doi: 10.4274/mirt.349
35. Allen NB, Cox CC, Kisslo J, et al. Use of immunosuppressive agents in the treatment of severe ocular and vascular manifestations of Cogan's syndrome. Am J Med. 1990;88(3):296-301. doi: 10.1016/0002-9343(90)90157-9
36. Pouchot J, Vinceneux P, Bouccara D, et al. Methotrexate as a steroid-sparing agent in Cogan's syndrome: comment on the concise communication by Richardson. Arthritis Rheum. 1995;38(9):1348-9. doi: 10.1002/art.1780380936
37. Riente L, Taglione E, Berrettini S. Efficacy of methotrexate in Cogan's syndrome. J Rheumatol. 1996;23(10):1830-1.
38. Pherwani A, Bansal S, Agrawal S, Gillow T. Cystoid macular oedema in Cogans syndrome – a case report. Cases J. 2008;1(1):339. doi: 10.1186/1757-1626-1-339
39. Jancatova D, Zelenik K, Kominek P, Matousek P. Atypical Cogan's syndrome: a case report and summary of current treatment options. Int J Pediatr Otorhinolaryngol. 2015;79(3):428-31. doi: 10.1016/j.ijporl.2014.12.028
40. Hautefort C, Loundon N, Montchilova M, et al. Mycophenolate mofetil as a treatment of steroid dependent Cogan's syndrome in childhood. Int J Pediatr Otorhinolaryngol. 2009;73(10):1477-9. doi: 10.1016/j.ijporl.2009.06.025
41. Orsoni JG, Lagana B, Rubino P, et al. Rituximab ameliorated severe hearing loss in Cogan's syndrome: a case report. Orphanet J Rare Dis. 2010;5:18. doi: 10.1186/1750-1172-5-18
42. Matteson EL, Choi HK, Poe DS, et al. Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study. Arthritis Rheum. 2005;53:337-42. doi: 10.1002/art.21179
43. Fricker M, Baumann F, Wermelinger F, et al. A novel therapeutic option in Cogan diseases? TNF-a blockers. Rheumatol Int. 2007;27:493-5. doi: 10.1007/s00296-006-0252-y
44. Ghadban R, Couret M, Zenone T. Efficacy of infliximab in Cogan's syndrome. J Rheumatol. 2008;35:2456-8. doi: 10.3899/jrheum.080203
45. Minet M, Deggouji N, Gersdorff M. Cochlear implantation in patients with Cogan's syndrome: a review of four cases. Eur Arch Otorhinolaryngol. 1997;254:459-62. doi: 10.1007/BF02439981
46. Bacciu A, Pasanisi E, Di Lella F, et al. Cochlear implantation in patients with Cogan syndrome: long-term results. Eur Arch Otorhinolaryngol. 2015;272(11):3201-7. doi: 10.1007/s00405-014- 3376-9
47. Ellis T, Nichani J, Mawman D, et al. Cochlear implantation in Cogan's syndrome. Int Adv Otol. 2012;8(2):311-6.
Для цитирования:
Бекетова Т.В. Синдром Когана – новая нозология в современной классификации системных васкулитов. Клиническое наблюдение и обзор литературы. Научно-практическая ревматология. 2016;54(4):463-468. https://doi.org/10.14412/1995-4484-2016-463-468
For citation:
Beketova T.V. Cogan's syndrome is a new nosological entity in the current classification of systemic vasculitides: A clinical case and a review of literature. Rheumatology Science and Practice. 2016;54(4):463-468. (In Russ.) https://doi.org/10.14412/1995-4484-2016-463-468
Просмотров: 868
Послать статью по эл. почте 
